Ocuphire Pharma
topline phase results | Ocuphire Pharma
Company
Deck Type
Deck date
March 2022
Slide
13 of 38
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
June 2021
topline phase results randomized center double masked placebo controlled study of the safety and efficacy of ophthalmic solution low dose pilocarpine for the treatment of presbyopia | Ocuphire Pharma
Results
March 2021
topline phase results randomized parallel arm double masked placebo controlled study of the safety and efficacy of ophthalmic solution to reverse pharmacologically induced mydriasis in healthy subjects | Ocuphire Pharma
Related slides by other companies
Xeris Biopharma
Investor Presentation
October 2022
topline results of phase study of | Xeris Biopharma
PaxMedica
Investor Presentation
October 2022
pax phase trial summary results | PaxMedica
argenx SE
Investor Presentation
November 2023
together we discover | argenx SE
Aeglea BioTherapeutics
Results
December 2021
the potential of human enzyme therapeutics | Aeglea BioTherapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights